"Global Anti-Obesity Drug Market Overview:
Global Anti-Obesity Drug Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Anti-Obesity Drug Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Anti-Obesity Drug involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Anti-Obesity Drug Market:
The Anti-Obesity Drug Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Anti-Obesity Drug Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Anti-Obesity Drug Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Anti-Obesity Drug market has been segmented into:
Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs
By Application, Anti-Obesity Drug market has been segmented into:
Prescription Drugs and OTC Drugs
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Anti-Obesity Drug market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Anti-Obesity Drug market.
Top Key Players Covered in Anti-Obesity Drug market are:
VIVUS Inc.
Pfizer Inc.
Novo Nordisk
Bayer AG
F Hoffmann-La Roche
Glaxosmithkline
Arena Pharmaceuticals
Eisai Co. Ltd.
Takeda Pharmaceutical Company
Nalpropion Pharmaceuticals Inc.
among others.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Anti-Obesity Drug Market by Type
4.1 Anti-Obesity Drug Market Snapshot and Growth Engine
4.2 Anti-Obesity Drug Market Overview
4.3 Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs: Geographic Segmentation Analysis
Chapter 5: Anti-Obesity Drug Market by Application
5.1 Anti-Obesity Drug Market Snapshot and Growth Engine
5.2 Anti-Obesity Drug Market Overview
5.3 Prescription Drugs and OTC Drugs
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Prescription Drugs and OTC Drugs: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Anti-Obesity Drug Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 VIVUS INC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 PFIZER INC.
6.4 NOVO NORDISK
6.5 BAYER AG
6.6 F HOFFMANN-LA ROCHE
6.7 GLAXOSMITHKLINE
6.8 ARENA PHARMACEUTICALS
6.9 EISAI CO. LTD.
6.10 TAKEDA PHARMACEUTICAL COMPANY
6.11 AND NALPROPION PHARMACEUTICALS INC.
6.12 AMONG OTHERS.
Chapter 7: Global Anti-Obesity Drug Market By Region
7.1 Overview
7.2. North America Anti-Obesity Drug Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Prescription Drugs and OTC Drugs
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Anti-Obesity Drug Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Prescription Drugs and OTC Drugs
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Anti-Obesity Drug Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Prescription Drugs and OTC Drugs
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Anti-Obesity Drug Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Prescription Drugs and OTC Drugs
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Anti-Obesity Drug Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Prescription Drugs and OTC Drugs
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Anti-Obesity Drug Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Prescription Drugs and OTC Drugs
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Anti-Obesity Drug Scope:
|
Report Data
|
Anti-Obesity Drug Market
|
|
Anti-Obesity Drug Market Size in 2025
|
USD XX million
|
|
Anti-Obesity Drug CAGR 2025 - 2032
|
XX%
|
|
Anti-Obesity Drug Base Year
|
2024
|
|
Anti-Obesity Drug Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc., among others..
|
|
Key Segments
|
By Type
Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs
By Applications
Prescription Drugs and OTC Drugs
|
